Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by gregoooon Mar 27, 2012 8:49pm

311 Views

Post# 19725560

RE: RE: RE: RE: Expect a move up now. IMHO. Eom

emulsion is with Canaguay - usually caused by mixing formation fluids from different formations- temperature/pressure drops-water/oil and thus emulsions-usually found at surface and then treated with chemicals and heat-I think they have solved this one by lowering the ESP to 12,000 ft and eliminating the upper and lower mirador from comingling before being pumped-time will tell. they are getting close to the max depth for an esp- I believe it is about 15000 ft.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale